Musculoskeletal Diseases
Conditions
Interventions
KASE Cream
Sponsors
Institut de Recherche en Sciences de la Sante
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Not be a patient suffering from osteoarthritis and/or tendinopathies Not be undergoing anti-inflammatory treatment Have no renal or hepatic impairment Be at least 20 years old Be able to apply the cream Reside in the study area (Ouagadougou) Agree to participate in the study
Exclusion criteria
Exclusion criteria: Suffering from pain related to inflammatory or tendon-ligament trauma, post-operative or post-traumatic edema (sprain, contusion), or osteoarthritis Pregnant or breastfeeding woman Patient refusing to sign the consent form Person with known allergies to the study drug or any of its components
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical: frequency and time of onset of effects (allergies, skin irritation, skin dryness, hypertensive episodes, etc.) Biological: alterations in parameters [Urea, Complete Blood Count (CBC), Transaminases (TRANSA), Creatinine (CREAT), Blood Glucose, etc.] Tolerance threshold: number of daily applications of the phytomedicine KASE Cream 1% tolerated | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical: Functional impact will be assessed using the WOMAC index. Changes in edema over time will be evaluated by perimetry. Changes in stiffness will be assessed by measuring the duration of stiffness. Biological: changes in CRP and ESR levels. | — |
Countries
Burkina Faso
Contacts
Public ContactBondo Felix Kini
Health Science research institute
Outcome results
None listed